Can Ketamine Help Benzodiazepine Withdrawal? - Melissa Bond & Dr. Amy de la Garza

This powerful episode of The Psychedelic Podcast explores the hidden crisis of benzodiazepine dependence and the emerging role of low-dose ketamine in withdrawal recovery. Melissa Bond, a narrative journalist and memoirist, shares her harrowing personal journey of becoming dependent on Ativan after a series of life crises, including childbirth, job loss, and marital strain. Despite being prescribed the drug for short-term insomnia, she developed severe physiological dependence within months, leading to debilitating withdrawal symptoms—neurological dysfunction, cognitive decline, and physical collapse—long after stopping use. Her story highlights how benzodiazepines, often dismissed as safe, can cause prolonged, life-altering withdrawal that is frequently misunderstood by the medical system. Dr. Amy de la Garza, a board-certified addiction and functional medicine physician, joins to explain the science behind benzodiazepine dependence, distinguishing it from addiction, and critiques the healthcare system’s overreliance on short-term prescriptions without long-term recovery support. The turning point comes when Dr. de la Garza discovers ketamine’s potential through a conference talk and applies a microdosing protocol to help Melissa safely taper off her final five milligrams of diazepam in just six weeks—something previously deemed impossible. The episode underscores the need for integrated, whole-person care that combines functional medicine, lifestyle interventions, and emerging psychedelic therapies to address the neurological damage caused by long-term benzodiazepine use. It concludes with a call for more research, systemic change, and accessible treatment models. Key takeaways include: 1) Benzodiazepines can cause severe, prolonged withdrawal even when taken as prescribed, often mistaken for mental illness; 2) The standard medical system lacks support for long-term tapering, leaving patients stranded; 3) Low-dose ketamine microdosing shows promise in reducing withdrawal suffering and enabling safe tapering; 4) A holistic approach—nutrition, sleep, mindfulness, and neuroplasticity support—is essential for recovery; 5) There is an urgent need for clinical research on ketamine’s neuroregenerative potential; 6) Patients must be empowered with accurate information to avoid the cycle of dependence; 7) Functional and integrative medicine offers a more sustainable path than traditional psychiatric models; 8) Community and peer support are critical, especially for single parents and caregivers navigating recovery.